EUVIMEDEUVIMED entdecken
Crossref

Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR)

Murilo de Santana Hager, Chloe Cottone, Paula Valeria Guerra Navarro, Ryan Dewan, Nicole Favre, Mohamed Elrakhawy, Michele M Carr

European Archives of Oto-Rhino-Laryngology · 2026-10 · 283 (11) · 7099-7103

DOI: 10.1007/s00405-026-10491-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 10.08.2026. Verfasst von Murilo de Santana Hager und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo, 955 Main St, Buffalo, NY, 14203, USA. murilode@buffalo.edu. Hauptthemen laut MEDLINE: Hyperthyroidism, Hearing Loss, Sensorineural, Antithyroid Agents, Hearing Loss. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the association between teprotumumab use and hearing loss in hyperthyroid patients using real-world, population-level data. METHODS: A retrospective cohort study using the TriNetX Collaborative Network was used to identify patients with hyperthyroidism (ICD-10 code E05) from 2006 to 2024. Two groups were established: one comprised of patients treated with teprotumumab and a control group of patients not treated with teprotumumab. Hearing loss was categorized as sensorineural (ICD-10 H90.A2, H90.A3, H90.A4, H90.A5), mixed (ICD-10 H90.A3, H90.A6, H90.A7, H90.A8), conductive (ICD-10 H90.0, H90.A1, H90.1, H90.2), or unspecified (ICD-10 H91.9). Cases of hearing loss occurring after teprotumumab initiation (in the treated group) or after hyperthyroidism diagnosis (in the control group) were recorded. Relative risk was calculated within a 95% confidence interval. Groups were propensity score matched for age and gender. RESULTS: A total of 2,164 patients were included (1,082 per cohort; mean age 55.9 years, SD = 14.6), with 793 (73.3%) female and 258 (23.8%) male in each group. Sensorineural hearing loss occurred in 154 (14.2%) of Teprotumumab users versus 51 (4.7%) of controls (P < .001), corresponding to a relative risk (RR) of 3.15 (95% CI: 2.31-4.27). Unspecified hearing loss was reported in 78 (7.2%) Teprotumumab patients versus 47 (4.3%) controls (P = .006; RR = 1.66; 95% CI: 1.17-2.36). Conductive and mixed hearing loss could not be reliably analyzed due to small sample sizes (N < 10 per group). CONCLUSION: Teprotumumab use is associated with a significantly increased risk of sensorineural and unspecified hearing loss in patients with hyperthyroidism. These findings support routine audiologic monitoring during treatment and highlight the need for prospective studies to investigate underlying mechanisms and preventative strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperthyroidismHearing Loss, SensorineuralAntithyroid AgentsHearing LossHumansFemaleMaleRetrospective StudiesMiddle AgedAdultAged

Stichwörter der Autor:innen

HearingHyperthyroidismIGF-1R inhibitionOtotoxicitySensorineural hearing lossTepezzaTeprotumumab

Substanzen

Antithyroid Agents

Autor:innen und Institutionen

  • Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo, 955 Main St, Buffalo, NY, 14203, USA. murilode@buffalo.edu.
  • Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo, 955 Main St, Buffalo, NY, 14203, USA.
  • Department of Otolaryngology, Jacobs School of Medicine and Biomedical Sciences, the University at Buffalo, 1001 Main St, Buffalo, 14203, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, IL, USA.

Zitieren

APA

de Santana Hager, M., Cottone, C., Guerra Navarro, P. V., Dewan, R., Favre, N., Elrakhawy, M., & Carr, M. M. (2026). Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR). European Archives of Oto-Rhino-Laryngology, 283(11), 7099-7103. https://doi.org/10.1007/s00405-026-10491-7

Vancouver

de Santana Hager M, Cottone C, Guerra Navarro PV, Dewan R, Favre N, Elrakhawy M, et al. Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR). European Archives of Oto-Rhino-Laryngology. 2026;283(11):7099-7103. doi:10.1007/s00405-026-10491-7

BibTeX
@article{deSantanaHager2026,
  author = {de Santana Hager, Murilo and Cottone, Chloe and Guerra Navarro, Paula Valeria and Dewan, Ryan and Favre, Nicole and Elrakhawy, Mohamed and Carr, Michele M},
  title = {Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR)},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  volume = {283},
  number = {11},
  pages = {7099--7103},
  doi = {10.1007/s00405-026-10491-7}
}
Kostenlos starten →